Hibernation and congestive heart failure

Heart Failure Reviews

Volumn 8, Issue 2, 2003, Pages 167-173

  Dutka, David P ^b   Camici, Paolo G ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cardiac imaging; Congestive heart failure; Coronary artery disease; Coronary revascularisation; Myocardial ischaemia; Ventricular function

Indexed keywords

PERHEXILINE; TRIMETAZIDINE;

CELL LOSS; CHRONIC DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DRUG TOXICITY; HEART ARRHYTHMIA; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE BLOOD FLOW; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL CARE; MORTALITY; MYOCARDIAL HIBERNATION; NORMAL VALUE; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; SCAR FORMATION; STUNNED HEART MUSCLE; SURVIVAL; TISSUE REPAIR;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY ARTERIOSCLEROSIS; CORONARY CIRCULATION; HEART FAILURE, CONGESTIVE; HUMANS; INCIDENCE; MYOCARDIAL CONTRACTION; MYOCARDIAL STUNNING; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0038216668     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023096903298     Document Type: Review

References (49)

1. McMurray JJV, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: Public and private health burden. Eur Heart J 1998;19:P9-P16.
2. Wijns W, Vatner SF, Camici PG. Hibernating myocardium. N Engl J Med 1998;339:173-181.
3. Clarke KW, Gray D, Hampton JR. How common is heart failure? Evidence from PACT (Prescription Analysis and Cost) data in Nottingham. Journal of Public Health Medicine 1995;17:459-464.
4. Cleland JGF. Health economic consequences of the pharmacological treatment of heart failure. Eur Heart J 1998;19:P32-P39.
5. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996;94:2817-2825.
6. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM et al. The effect of carvedilol on mordity and mortality in patients with chronic heart failure. New Engl J Med 1996;334:1349-1355.
7. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II). Lancet 1999;35:9-13.
8. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New Engl J Med 1999;341:709-717.
9. Ziesche S, Cobb FR, Cohn JN, Johnson G, Trisani F, Hydalazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. Circulation 1993;87(suppl VI):VI-56-VI-64.
10. Pagano D, Lewis ME, Townend JN, Camici PG, Bonser RS. Revascularisation for post-ischaemic heart failure: How myocardial viability affects survival. Heart 1999;82:684-688.
11. Tennant R, Wiggers CJ. Effect of coronary occlusion on myocardial contraction. Am J Physiol 1935;112:351-361.
12. Heyndrickx GR, Millard RW, McRitchie RJ, Maroko PR, Vatner SF. Regional myocardial functional and electro-physiological alterations after brief coronary artery occlusion in conscious dogs. J Clin Invest 1975;56:978-985.
13. Ambrosio G, Betocchi S, Pace L, Losi MA, Perrone Filardi P, Soricelli A et al. Prolonged impairment of regional contractile function after resolution of exercise-induced angina. Evidence of myocardial stunning in patients with coronary artery disease. Circulation 1996;94:2455-2464.
14. Barnes E, Baker CS, Dutka DP, Rimoldi O, Rinaldi CA, Nihoyannopoulos P et al. Prolonged left ventricular dysfunction occurs in patients with coronary artery disease after both dobutamine and exercise induced myocardial ischaemia. Heart 2000;83:283-289.
15. Barnes E, Hall RJC, Dutka DP, Camici PG. Absolute blood flow and oxygen consumption in stunned myocardium in patients with coronary artery disease. J Am Coll Cardiol 2002;39:420-427.
16. Barnes E, Dutka DP, Khan M, Camici PG, Hall RJC. The assessment of repetitive episodes of reversible myocardial ischemia on myocardial blood flow and myocardial function in man. Am J Physiol 2002;282:H1603-H1608.
17. Horn HR, Teichholz LE, Cohn PF, Herman MV, Gorlin R. Augmentation of left ventricular contraction pattern in coronary artery disease by an inotropic catecholamine. The epinephrine ventriculogram. Circulation 1974;49:1063-1071.
18. Diamond GA, Forrester JS, DeLuz PL, Wyatt HL, Swan HJC. Postextrasystolic potentiation of ischemic myocardium by atrial stimulation. Am Heart J 1978;95:204-209.
19. Rahimtoola SH. A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circulation 1985;72:V123-V135.
20. Conversano A, Walsh JF, Geltman EM, Perez JE, Bergmann SR, Gropler RJ. Delineation of myocardial stunning and hibernation by positron emission tomography in advanced coronary artery disease. Am Heart J 1996;131:440-450.
21. De Silva R, Yamamoto Y, Rhodes CG, Iida H, Nihoyannopoulos P, Davies GJ et al. Preoperative prediction of the outcome of coronary revascularization using positron emission tomography. Circulation 1992;86:1738-1742.
22. Gerber BL, Vanoverschelde JL, Bol A, Michel C, Labar D, Wijns W et al. Myocardial blood flow, glucose uptake, and recruitment of inotropic reserve in chronic left ventricular ischemic dysfunction. Implications for the patho-physiology of chronic myocardial hibernation. Circulation 1996;94:651-659.
23. Grandin C, Wijns W, Melin JA, Bol A, Robert AR, Heyndrickx GR et al. Delineation of myocardial viability with PET. J Nucl Med 1995;36:1543-1552.
24. Maki M, Luotolahti M, Nuutila P, Iida H, Voipio Pulkki LM, Ruotsalainen U et al. Glucose uptake in the chronically dysfunctional but viable myocardium. Circulation 1996;93:1658-1666.
25. Marinho NV, Keogh BE, Costa DC, Lammerstma AA, Ell PJ, Camici PG. Pathophysiology of chronic left ventricular dysfunction. New insights from the measurement of absolute myocardial blood flow and glucose utilization. Circulation 1996;93:737-744.
26. Sambuceti G, Parodi O, Marcassa C, Neglia D, Salvadori P, Giorgetti A et al. Alteration in regulation of myocardial blood flow in one-vessel coronary artery disease determined by positron emission tomography. Am J Cardiol 1993;72:538-543.
27. Sun KT, Czernin J, Krivokapich J, Lau YK, Bottcher M, Maurer G et al. Effects of dobutamine stimulation on myocardial blood flow, glucose metabolism, and wall motion in normal and dysfunctional myocardium. Circulation 1996;94:3146-3154.
28. Vanoverschelde JL, Wijns W, Depre C, Essamri B, Heyndrickx GR, Borgers M et al. Mechanisms of chronic regional postischemic dysfunction in humans. New insights from the study of noninfarcted collateral-dependent myocardium. Circulation 1993;87:1513-1523.
29. Camici PG, Wijns W, Borgers M, De Silva R, Ferrari R, Knuuti J, Lammertsma AA, Liedtke AJ, Paternostro G, Vatner SF. Pathophysiological mechanisms of chronic reversible left ventricular dysfunction due to coronary artery disease (hibernating myocardium). Circulation 1997;96:3205-3214.
30. Uren NG, Melin JA, De Bruyne B, Wijns W, Baudhuin T, Camici PG. Myocardial blood flow as a function of coronary stenosis severity in man. New Engl J Med 1994;330:1782-1788.
31. Camici PG, Dutka DP. Repetitive stunning, hibernation and heart failure: The contribution of PET to establishing a link. Am J Physiol 2001;280:H929-H936.
32. Bonow RO. The hibernating myocardium: Implications for management of congestive heart failure. Am J Cardiol 1995;75:17A-25A.
33. Eitzman D, Al Aouar Z, Kanter HL, Vom Dahl J, Kirsh M, Deeb GM et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol 1992;20:559-565.
34. Pagano D, Bonser RS, Townend JN, Ordoubadi F, Lorenzoni R, Camici PG. Predictive value of dobutamine echocardiography and positron emission tomography in identifying hibernating myocardium in patients with postischaemic heart failure. Heart 1998;79:281-288.
35. Samady H, Elefteriades JA, Abbott BG, Mattera JA, McPherson CA, Wackers FJTH. Failure to improve left ventricular function after coronary revascularisation for ischaemic cardiomyopathy is not associated with a worse outcome. Circulation 1999;100:1298-1304.
36. Pagano D, Townend JN, Littler WA, Horton R, Camici PG, Bonser RS. Coronary artery bypass surgery as treatment for ischemic heart failure: The predictive value of viability assessment with quantitative positron emission tomography for symptomatic and functional outcome. J Thorac Cardiovasc Surg 1998;115:791-799.
37. Vom Dahl J, Eitzman DT, Al Aouar ZR, Kanter HL, Hicks RJ, Deeb GM et al. Relation of regional function, perfusion, and metabolism in patients with advanced coronary artery disease undergoing surgical revascularization. Circulation 1994;90:2356-2366.
38. Pagley PR, Beller GA, Watson DD, Gimple LW, Ragosta M. Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability. Circulation 1997;96:793-800.
39. Dreyfus GD, Duboc D, Blasco A, Vigoni F, Dubois C, Brodaty D et al. Myocardial viability assessment in ischemic cardiomyopathy: Benefits of coronary revascularization. Ann Thorac Surg 1994;57:1402-1407.
40. Di Carli MF, Asgarzadie F, Schelbert HR, Brunken RC, Laks H, Phelps ME et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation 1995;92:3436-3444.
41. Bonow RO. Identification of viable myocardium. Circulation 1996;94:2674-2680.
42. Armstrong WF, Pellikka PA, Ryan T, Crouse L, Zoghbi WA. Stress echocardiography: Recommendations for performance and interpretation of stress echocardiography. Stress echocardiography task force of the nomenclature and standards committee of the American society of echocardiography. J Am Soc Echocardiogr 1998;11:97-104.
43. Camici P, Ferrannini E, Opie LH. Myocardial metabolism in ischemic heart disease: Basic principles and application to imaging by positron emission tomography. Prog Cardiovasc Dis 1989;32:217-238.
44. Wolff AA, Rotmensch HH, Stanley WC, Ferrari R. Metabolic approaches to the treatment of ischemic heart disease: The clinicians' perspective. Heart Fail Rev 2002;7:187-203.
45. Alderman EL, Fisher LD, Litwin P, Kaiser GC, Myers WO, Maynard C et al. Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circulation 1983;68:785-795.
46. Rees G, Bristow JD, Kremkau EL, Green GS, Herr RH, Griswold HE et al. Influence of aortocoronary bypass surgery on left ventricular performance. N Engl J Med 1971;284:1116-1120.
47. Elsasser A, Schlepper M, Klovekorn WP, Cai WJ, Zimmermann R, Muller KD et al. Hibernating myocardium: An incomplete adaptation to ischemia. Circulation 1997;96:2920-2931.
48. Schwarz ER, Schaper J, Vom Dahl J, Altehoefer C, Grohmann B, Schoendube F et al. Myocyte degeneration and cell death in hibernating human myocardium. J Am Coll Cardiol 1996;27:1577-1585.
49. Pagano D, Fath-Ordoubadi F, Beatt KJ, Townend JN, Bonser RS, Camici PG. Effects of coronary revascularisation on myocardial blood flow and coronary vasodilator reserve in hibernating myocardium. Heart 2001;85:208-212.